Tag:
iniparib
Latest Headlines
Latest Headlines
Sanofi preps for new pivotal trial of a blockbuster hopeful
One of the biggest pipeline setbacks Sanofi has experienced recently has been the failure of its high-profile Phase III breast cancer trial for iniparib back in January. Iniparib was the jewel in
Sanofi breast cancer drug flunks Phase III trial
Sanofi subsidiary BiPar Sciences says its metastatic breast cancer drug iniparib (BSI-201) failed a late-stage trial, missing the co-primary endpoints of overall survival and progression-free
